Dactylitis

Working group OMERACT > 

MENTOR:

Maria Antonietta D´Agostino

Convenors: E Naredo, I Möller, G Kaeley, S Aydin

Website responsible: E Naredo

Objective of the subgroup work: 

The main objective of this group is to develop an ultrasound dactylitis scoring system as an imaging instrument for clinical trials and longitudinal observational studies in psoriatic arthritis (PsA). 

What is the contribution of the subgroup work to the OMERACT work?

Contribution to the Psoriatic Arthritis Working Group. Musculoskeletal disease activity, including peripheral joints, dactylitis, enthesitis, and spine symptoms is a domain of the updated 2016 PsA Core Domain Set. Ultrasound can be an imaging instrument to measure dactylitis on PsA.

Description of the previous work

The dactylitis subgroup has produced 2012 the following:

1.     Literature review on dactylitis already published, i.e.  Bakewell CJ, Olivieri I, Aydin SZ, Dejaco C, Ikeda K, Gutierrez M, Terslev L, Thiele R, D'Agostino MA, Kaeley GS; OMERACT Ultrasound Task Force. Ultrasound and magnetic resonance imaging in the evaluation of psoriatic dactylitis: status and perspectives. J Rheumatol 2013.

2.     Validation of ultrasound digital entheses in specimens (gross anatomy and histology as gold standard).

3.     Consensus on digital entheses (suitable for ultrasound assessment and involved in PsA) to be included in the OMERACT dactylitis scoring system based on Delphi methodology.

4.     Consensus on ultrasound lesions component of dactylitis based on Delphi methodology.

5.     Consensus on scoring system for ultrasound lesions component of dactylitis.

6.     Development of a consensus-based Global OMERACT Ultrasound Dactylitis Score (GLOUDAS) in PsA.

7.     Assessment of the intra- and interobserver reliability of GLOUDAS (results available soon).

Reporting back on work done since ACR 2017

N/A

Next steps and discussion points

Planned agenda:

1. June-December 2023: to publish the results of the development process and reliability of GLOUDAS.

2. January 2024: to test the responsiveness of GLOUDAS in longitudinal studies.